Mesoblast (MESO) Return on Capital Employed (2017 - 2023)
Mesoblast recorded quarterly Return on Capital Employed of 209.22% in Q2 2023, up 2.77% quarter-over-quarter from 215.19% in Q1 2023, and up 12335.0% year-over-year from N/an in Q2 2022.
Mesoblast's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 209.22% for Q2 2023.
- In Q2 2023, Return on Capital Employed rose 12335.0% year-over-year to 209.22%; the TTM figure through Jun 2023 stood at 209.22% (up 12335.0% YoY), while the FY2025 annual figure was 9.94%, up 92.0% from the prior year.
- Return on Capital Employed came in at 209.22% for Q2 2023 at Mesoblast, up from 215.19% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 822.31% in Q2 2021 to a low of 368.88% in Q1 2020.
- A 5-year average of 19.22% and a median of 199.79% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 83040 bps in 2021 and tumbled 115487 bps in 2022, its largest moves.
- Mesoblast's Return on Capital Employed stood at 306.35% in 2019, then soared by 158 bps to 176.64% in 2020, then surged by 195 bps to 521.85% in 2021, then sank by 136 bps to 190.36% in 2022, then dropped by 10 bps to 209.22% in 2023.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 209.22%, 215.19%, and 190.36% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -209.22% |
| Mar 31, 2023 | -215.19% |
| Dec 31, 2022 | -190.36% |
| Sep 30, 2022 | -213.27% |
| Jun 30, 2022 | -332.56% |
| Mar 31, 2022 | 777.12% |
| Dec 31, 2021 | 521.85% |
| Sep 30, 2021 | 688.27% |
| Jun 30, 2021 | 822.31% |
| Mar 31, 2021 | 102.16% |
| Dec 31, 2020 | 176.64% |
| Sep 30, 2020 | 52.05% |
| Jun 30, 2020 | -8.09% |
| Mar 31, 2020 | -368.88% |
| Dec 31, 2019 | -306.35% |
| Sep 30, 2019 | -308.73% |
| Jun 30, 2019 | -325.95% |
| Mar 31, 2019 | -315.81% |
| Dec 31, 2018 | -314.82% |
| Sep 30, 2018 | -412.89% |
| Jun 30, 2018 | -322.36% |
| Mar 31, 2018 | -329.95% |
| Dec 31, 2017 | -208.18% |
| Sep 30, 2017 | 8.38% |
| Jun 30, 2017 | 7.76% |
| Mar 31, 2017 | 10.49% |